Related Experiment Videos
Interferon beta-1a in children with multiple sclerosis is well tolerated
E Waubant1, J Hietpas, T Stewart
1UCSF/Mt Zion Multiple Sclerosis Center, San Francisco, CA, USA. emmanuelle.waubant@psl.ap-hop-paris.fr
Insights
Weekly interferon beta-1a (IFNB-1 a) injections were well tolerated in children with relapsing-remitting multiple sclerosis (RRMS). No patients discontinued treatment due to adverse events, suggesting a favorable safety profile for pediatric MS management.
Area of Science:
- Neurology
- Pediatric Medicine
- Immunology
Background:
- Multiple sclerosis (MS) is a chronic demyelinating neurological disorder.
- Pediatric MS is rare, and treatment options for children are limited.
- Current disease-modifying therapies for MS are primarily approved for adult use.
Purpose of the Study:
- To assess the tolerability of interferon beta-1a (IFNB-1 a) in pediatric patients with relapsing-remitting MS (RRMS).
- To evaluate the safety and feasibility of weekly intramuscular IFNB-1 a injections in children under 16 years old.
Main Methods:
- A survey was distributed to US neurologists to gather data on IFNB-1 a tolerability in pediatric MS patients.
- Data were collected from neurologists who initiated IFNB-1 a treatment in patients younger than 16 years.
- Tolerability was assessed based on treatment continuation and reasons for discontinuation.
Main Results:
- Tolerability data were obtained for 9 pediatric patients initiating IFNB-1 a treatment.
- The mean age of patients starting treatment was 12.7 years, with a treatment duration averaging 17 months.
- No patients discontinued IFNB-1 a therapy due to adverse events, indicating good tolerability.
Conclusions:
- Weekly intramuscular IFNB-1 a injections demonstrate preliminary tolerability in children with RRMS.
- The findings suggest IFNB-1 a may be a viable treatment option for pediatric MS patients.
- Further research is warranted to confirm long-term efficacy and safety in this population.
Background:
Multiple sclerosis is a chronic demyelinating disease rare in children. Currently marketed disease modifying therapies are limited to adults.
Objective:
To determine the tolerability of interferon beta-1a (IFNB-1 a) 30 mcg injected intramuscularly once a week in children with clinically definite relapsing-remitting multiple sclerosis (RRMS).
Design/Methods:
A standardized questionnaire was sent to neurologists in the United States to determine the tolerability of IFNB-1 a in patients younger than 16 years.
Results:
Tolerability data were available for 9 of 33 children who were reported to initiate IFNB-1 a. Mean age on initiating treatment was 12.7 years (range 8 - 15) and mean duration of therapy was 17 months (range 5 - 36). No patient discontinued therapy due to an adverse event.
Conclusions:
Preliminary data indicate that weekly intramuscular injections of IFNB-1 a are well tolerated.